RhumbLine Advisers’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-72,806
| Closed | -$4.94M | – | 2967 |
|
|
2019
Q3 | $4.94M | Buy |
72,806
+35,392
| +95% | +$2.43M | 0.01% | 1192 |
|
|
2019
Q2 | $2.18M | Buy |
37,414
+6,812
| +22% | +$404K | ﹤0.01% | 1692 |
|
|
2019
Q1 | $2.14M | Buy |
30,602
+895
| +3% | +$66.4K | ﹤0.01% | 1664 |
|
|
2018
Q4 | $1.91M | Buy |
29,707
+7,974
| +37% | +$559K | ﹤0.01% | 1672 |
|
|
2018
Q3 | $1.53M | Sell |
21,733
-260
| -1% | -$15.2K | ﹤0.01% | 1803 |
|
|
2018
Q2 | $1.11M | Buy |
21,993
+1,310
| +6% | +$52K | ﹤0.01% | 1963 |
|
|
2018
Q1 | $647K | Sell |
20,683
-340
| -2% | -$11.3K | ﹤0.01% | 2117 |
|
|
2017
Q4 | $719K | Sell |
21,023
-3,911
| -16% | -$125K | ﹤0.01% | 2092 |
|
|
2017
Q3 | $800K | Buy |
24,934
+270
| +1% | +$8.52K | ﹤0.01% | 2089 |
|
|
2017
Q2 | $803K | Buy |
24,664
+1,296
| +6% | +$41.1K | ﹤0.01% | 2064 |
|
|
2017
Q1 | $736K | Buy |
23,368
+502
| +2% | +$14.9K | ﹤0.01% | 2073 |
|
|
2016
Q4 | $672K | Buy |
22,866
+1,250
| +6% | +$38.1K | ﹤0.01% | 2070 |
|
|
2016
Q3 | $625K | Buy |
21,616
+55
| +0.3% | +$1.53K | ﹤0.01% | 2073 |
|
|
2016
Q2 | $558K | Buy |
21,561
+805
| +4% | +$21.4K | ﹤0.01% | 2128 |
|
|
2016
Q1 | $514K | Buy |
20,756
+70
| +0.3% | +$1.92K | ﹤0.01% | 2201 |
|
|
2015
Q4 | $728K | Buy |
20,686
+930
| +5% | +$24.9K | ﹤0.01% | 2014 |
|
|
2015
Q3 | $418K | Buy |
19,756
+7
| +0% | +$180 | ﹤0.01% | 2355 |
|
|
2015
Q2 | $549K | Buy |
19,749
+25
| +0.1% | +$705 | ﹤0.01% | 2264 |
|
|
2015
Q1 | $603K | Buy |
19,724
+2,300
| +13% | +$73.1K | ﹤0.01% | 2177 |
|
|
2014
Q4 | $557K | Sell |
17,424
-400
| -2% | -$13K | ﹤0.01% | 2214 |
|
|
2014
Q3 | $505K | Sell |
17,824
-100
| -0.6% | -$2.79K | ﹤0.01% | 2212 |
|
|
2014
Q2 | $491K | Sell |
17,924
-520
| -3% | -$13.8K | ﹤0.01% | 2281 |
|
|
2014
Q1 | $486K | Sell |
18,444
-820
| -4% | -$23.5K | ﹤0.01% | 2250 |
|
|
2013
Q4 | $564K | Hold |
19,264
| – | – | ﹤0.01% | 2183 |
|
|
2013
Q3 | $589K | Sell |
19,264
-99
| -0.5% | -$3.31K | ﹤0.01% | 2110 |
|
|
2013
Q2 | $614K | Buy |
+19,363
| New | +$636K | ﹤0.01% | 2106 |
|
RhumbLine Advisers's GHDX Position: Q4 2019 in Review
RhumbLine Advisers sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 72,806 shares — an estimated $4.94M sold.
RhumbLine Advisers first reported a position in GHDX in Q2 2013 and held it in 26 quarters. The position peaked at $4.94M in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- RhumbLine Advisers reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- RhumbLine Advisers sold 72,806 Genomic Health, Inc. shares in Q4 2019, an estimated $4.94M.
- RhumbLine Advisers first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 26 quarters.
- RhumbLine Advisers's Genomic Health, Inc. position peaked at $4.94M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.